Expression of β-Catenin in Prostatic Adenocarcinomas: A Comparison with Colorectal Adenocarcinomas

American Journal of Clinical Pathology

Volumn 121, Issue 4, 2004, Pages 557-563

  Bismar, Tarek A ^a,b,c   Humphrey, Peter A ^a   Grignon, David J ^b   Wang, Hanlin L ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Adenocarcinoma; Colorectal; Immunohistochemistry; Prostate; Catenin

Indexed keywords

BETA CATENIN; CYTOKERATIN 20; CYTOKERATIN 7; PROSTATE SPECIFIC ANTIGEN; VILLIN;

ADULT; AGED; ARTICLE; COLORECTAL CANCER; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MEMBRANE STRUCTURE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE EPITHELIUM; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STAINING;

EID: 1642270365     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/447049GV52H7D258     Document Type: Article

References (38)

1. Kemler R. From cadherins to catenins: cytoplasmic protein interactions and regulation of cell adhesion. Trends Genet. 1993;9:317-321.
2. Willert K, Nusse R. β-Catenin: a key mediator of Wnt signaling. Curr Opin Genet Dev. 1998;8:95-102.
3. Bullions LC, Levine AJ. The role of beta-catenin in cell adhesion, signal transduction, and cancer. Curr Opin Oncol. 1998;10:81-87.
4. Morin PJ. β-Catenin signaling and cancer. Bioessays. 1999;21:1021-1030.
5. Wong NA, Pignatelli M. β-Catenin: a linchpin in colorectal carcinogenesis? Am J Pathol. 2002;160:389-401.
6. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell. 1996;87:159-170.
7. Morin PJ, Sparks AB, Korinek V, et al. Activation of β-catenin-Tcf signaling in colon cancer by mutations in β-catenin or APC. Science. 1997;275:1787-1790.
8. Sparks AB, Morin PJ, Vogelstein B, et al. Mutational analysis of the APC/β-catenin/Tcf pathway in colorectal cancer. Cancer Res. 1998;58:1130-1134.
9. Fearon ER. Human cancer syndromes: clues to the origin and nature of cancer. Science. 1997;278:1043-1050.
10. Chung DC. The genetic basis of colorectal cancer: insights into critical pathways of tumorigenesis. Gastroenterology. 2000;119:854-865.
11. Voeller HJ, Truica CI, Gelmann EP. β-Catenin mutations in human prostate cancer. Cancer Res. 1998;58:2520-2523.
12. Chesire DR, Ewing CM, Sauvageot J, et al. Detection and analysis of β-catenin mutations in prostate cancer. Prostate. 2000;45:323-334.
13. Suzuki H, Aida S, Akimoto S, et al. State of adenomatous polyposis coli gene and ras oncogenes in Japanese prostate cancer. Jpn J Cancer Res. 1994;85:847-852.
14. Watanabe M, Kakiuchi H, Kato H, et al. APC gene mutations in human prostate cancer. Jpn J Clin Oncol. 1996;26:77-81.
15. Gerstein AV, Almeida TA, Zhao G, et al. APC/CTNNB1 (β-catenin) pathway alterations in human prostate cancers. Genes Chromosomes Cancer. 2002;34:9-16.
16. Chesire DR, Ewing CM, Gage WR, et al. In vitro evidence for complex modes of nuclear β-catenin signaling during prostate growth and tumorigenesis. Oncogene. 2002;21:2679-2694.
17. Bierie B, Nozawa M, Renou JP, et al. Activation of β-catenin in prostate epithelium induces hyperplasias and squamous transdifferentiation. Oncogene. 2003;22:3875-3887.
18. Gounari F, Signoretti S, Bronson R, et al. Stabilization of β-catenin induces lesions reminiscent of prostatic intraepithelial neoplasia, but terminal squamous transdifferentiation of other secretory epithelia. Oncogene. 2002;21:4099-4107.
19. Culig Z, Klocker H, Bartsch G, et al. Androgen receptors in prostate cancer. J Urol. 2003;170:1363-1369.
20. Truica CI, Byers S, Gelmann EP. β-Catenin affects androgen receptor transcriptional activity and ligand specificity. Cancer Res. 2000;60:4709-4713.
21. Yang F, Li X, Sharma M, et al. Linking β-catenin to androgen-signaling pathway. J Biol Chem. 2002;277:11336-11344.
22. Song LN, Herrell R, Byers S, et al. β-Catenin binds to the activation function 2 region of the androgen receptor and modulates the effects of the N-terminal domain and TIF2 on ligand-dependent transcription. Mol Cell Biol. 2003;23:1674-1687.
23. Mulholland DJ, Cheng H, Reid K, et al. The androgen receptor can promote β-catenin nuclear translocation independently of adenomatous polyposis coli. J Biol Chem. 2002;277:17933-17943.
24. Pawlowski JE, Ertel JR, Allen MP, et al. Liganded androgen receptor interaction with β-catenin: nuclear co-localization and modulation of transcriptional activity in neuronal cells. J Biol Chem. 2002;277:20702-20710.
25. Chesire DR, Isaacs WB. Ligand-dependent inhibition of β-catenin/TCF signaling by androgen receptor. Oncogene. 2002;21:8453-8469.
26. Mulholland DJ, Read JT, Rennie PS, et al. Functional localization and competition between the androgen receptor and T-cell factor for nuclear β-catenin: a means for inhibition of the Tcf signaling axis. Oncogene. 2003;22:5602-5613.
27. Amir AL, Barua M, McKnight NC, et al. A direct β -catenin-independent interaction between androgen receptor and T cell factor 4. J Biol Chem. 2003;278:30828-30834.
28. Brabletz T, Herrmann K, Jung A, et al. Expression of nuclear β-catenin and c-myc is correlated with tumor size but not with proliferative activity of colorectal adenomas. Am J Pathol. 2000;156:865-870.
29. Wang HL, Wang J, Xiao SY, et al. Elevated protein expression of cyclin D1 and Fra-1 but decreased expression of c-myc in human colorectal adenocarcinomas overexpressing β-catenin. Int J Cancer. 2002;101:301-310.
30. De La Taille A, Rubin MA, Chen MW, et al. β-Catenin-related anomalies in apoptosis-resistant and hormone-refractory prostate cancer cells. Clin Cancer Res. 2003;9:1801-1807.
31. Bastacky SI, Wojno KJ, Walsh PC, et al. Pathological features of hereditary prostate cancer. J Urol. 1995;153:987-992.
32. Roose J, Clevers H. TCF transcription factors: molecular switches in carcinogenesis. Biochim Biophys Acta. 1999;1424:M23-M37.
33. Morita N, Uemura H, Tsumatani K, et al. E-cadherin and α-, β- and γ-catenin expression in prostate cancers: correlation with tumour invasion. Br J Cancer. 1999;79:1879-1883.
34. Arenas MI, Romo E, Royuela M, et al. E-, N- and P-cadherin, and α-, β- and γ-catenin protein expression in normal, hyperplastic and carcinomatous human prostate. Histochem J. 2000;32:659-667.
35. Kallakury BV, Sheehan CE, Winn-Deen E, et al. Decreased expression of catenins (α and β), p120 CTN, and E-cadherin cell adhesion proteins and E-cadherin gene promoter methylation in prostatic adenocarcinomas. Cancer. 2001;92:2786-2795.
36. Kallakury BV, Sheehan CE, Ross JS. Co-downregulation of cell adhesion proteins α- and β-catenins, p120CTN, E-cadherin, and CD44 in prostatic adenocarcinomas. Hum Pathol. 2001;32:849-855.
37. Athman R, Louvard D, Robine S. The epithelial cell cytoskeleton and intracellular trafficking, III: how is villin involved in the actin cytoskeleton dynamics in intestinal cells? Am J Physiol Gastrointest Liver Physiol. 2002;283:G496-G502.
38. Goldstein NS. Immunophenotypic characterization of 225 prostate adenocarcinomas with intermediate or high Gleason scores. Am J Clin Pathol. 2002;117:471-477.